Post-earnings recap
Reported
Tue, Nov 5, 2024
EPS actual
$-1.01
EPS est.
$-1.33
EPS surprise
+24.29%
1-day move
-0.45%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CRISPR Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock reacted negatively, declining by 0.45%. This could indicate that investors are concerned about the lack of revenue details and future guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.01 | N/A | +24.29% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a cautious optimism about future projects. They reiterated their commitment to innovation despite current challenges.
Management highlighted ongoing advancements in their pipeline.
They emphasized the importance of continued research and development efforts.